Ann Intensive Care:严重败血症和败血性休克患者,临床实践对降钙素原检测依从性低?

2018-07-06 王淳 环球医学

降钙素原(PCT)导向方案可以安全地指导危重病人的抗菌药治疗时间,但临床实践对方案的依从性缺少相关研究。2018年6月,发表在《Ann Intensive Care》的一项由德国学者进行的研究,考察了严重败血症和败血性休克患者中基于降钙素原(PCT)抗菌药治疗方案的依从性。

降钙素原(PCT)导向方案可以安全地指导危重病人的抗菌药治疗时间,但临床实践对方案的依从性缺少相关研究。2018年6月,发表在《Ann Intensive Care》的一项由德国学者进行的研究,考察了严重败血症和败血性休克患者中基于降钙素原(PCT)抗菌药治疗方案的依从性。

背景:在随机对照试验中,基于PCT的抗菌药治疗已被证实能明显减少重症监护室(ICU)患者的抗菌药治疗时间。但是,低方案依从性和较高的否决率引起关注,因此,研究条件外真实临床中基于PCT治疗的价值仍不清楚。在本研究中,分析严重败血症和败血性休克患者中应用PCT方案指导抗菌药治疗的依从性情况。

方法:从2012到2014年,回顾性筛选手术ICU中严重败血症或败血性休克患者的PCT检测系列,适合做出抗菌药治疗的决策。研究人员对比(1)适合PCT检测系列的患者vs不适合序列的患者;(2)达到抗菌药停用建议阈值的患者(PCT<0.5 ng/mL和/或峰水平下降10%)vs未达到停用建议阈值的患者;(3)依从于PCT方案的患者vs不依从治疗的患者。对比组间的抗菌药治疗持续时间、PCT动力学和其他临床结局。

结果:在81名严重败血症或败血性休克患者中,14名因治疗限制或ICU疗程短被排除。最终分析在67名患者中开展。42名患者(62.7%)具有适合的PCT检测序列。在适合PCT序列的患者中,最初PCT中位数(p=0.001)和PCT峰水平明显高于不适合序列。在26名适合序列的患者中,PCT水平达到抗菌药停用建议。26名停用建议患者中,8名(30.8%)依从于PCT方案停用抗菌药。依从于停用抗菌药的患者具有较短的抗菌药治疗时间(7d[IQR 6–9] vs.12d[IQR 9–16];p=0.002)。其他临床结局没有差异。

结论:在严重败血症和败血性休克患者中,降钙素原检测是非常规检测的的,并且在真实临床实践中实际PCT方案的依从性较低。但是,依从治疗的患者具有较短的抗菌药治疗时间且无不良临床结局。降钙素原峰值和动力学对PCT检测的规律性有明显影响。

原始出处:

Hohn A, Balfer N, Heising B, et,al. Adherence to a procalcitonin-guided antibiotic treatment protocol in patients with severe sepsis and septic shock. Ann Intensive Care. 2018 Jun 4;8(1):68. doi: 10.1186/s13613-018-0415-5.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2038937, encodeId=c686203893e39, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Nov 19 23:23:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331217, encodeId=fd3533121e4b, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Fri Jul 13 06:36:51 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277887, encodeId=657512e7887a5, content=<a href='/topic/show?id=464c98221e9' target=_blank style='color:#2F92EE;'>#降钙素原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98221, encryptionId=464c98221e9, topicName=降钙素原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Sun Jul 08 06:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319322, encodeId=67cf131932271, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Jul 08 06:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324053, encodeId=77a51324053e1, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Jul 08 06:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2038937, encodeId=c686203893e39, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Nov 19 23:23:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331217, encodeId=fd3533121e4b, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Fri Jul 13 06:36:51 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277887, encodeId=657512e7887a5, content=<a href='/topic/show?id=464c98221e9' target=_blank style='color:#2F92EE;'>#降钙素原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98221, encryptionId=464c98221e9, topicName=降钙素原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Sun Jul 08 06:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319322, encodeId=67cf131932271, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Jul 08 06:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324053, encodeId=77a51324053e1, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Jul 08 06:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=)]
    2018-07-13 张新亮1853311252142e2fm

    好文献学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2038937, encodeId=c686203893e39, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Nov 19 23:23:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331217, encodeId=fd3533121e4b, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Fri Jul 13 06:36:51 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277887, encodeId=657512e7887a5, content=<a href='/topic/show?id=464c98221e9' target=_blank style='color:#2F92EE;'>#降钙素原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98221, encryptionId=464c98221e9, topicName=降钙素原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Sun Jul 08 06:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319322, encodeId=67cf131932271, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Jul 08 06:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324053, encodeId=77a51324053e1, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Jul 08 06:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2038937, encodeId=c686203893e39, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Nov 19 23:23:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331217, encodeId=fd3533121e4b, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Fri Jul 13 06:36:51 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277887, encodeId=657512e7887a5, content=<a href='/topic/show?id=464c98221e9' target=_blank style='color:#2F92EE;'>#降钙素原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98221, encryptionId=464c98221e9, topicName=降钙素原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Sun Jul 08 06:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319322, encodeId=67cf131932271, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Jul 08 06:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324053, encodeId=77a51324053e1, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Jul 08 06:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=)]
    2018-07-08 fyxzlh
  5. [GetPortalCommentsPageByObjectIdResponse(id=2038937, encodeId=c686203893e39, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Mon Nov 19 23:23:00 CST 2018, time=2018-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331217, encodeId=fd3533121e4b, content=好文献学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b5a62240667, createdName=张新亮1853311252142e2fm, createdTime=Fri Jul 13 06:36:51 CST 2018, time=2018-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277887, encodeId=657512e7887a5, content=<a href='/topic/show?id=464c98221e9' target=_blank style='color:#2F92EE;'>#降钙素原#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98221, encryptionId=464c98221e9, topicName=降钙素原)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d521144, createdName=wrj0121, createdTime=Sun Jul 08 06:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1319322, encodeId=67cf131932271, content=<a href='/topic/show?id=60172686668' target=_blank style='color:#2F92EE;'>#依从性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26866, encryptionId=60172686668, topicName=依从性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9df476, createdName=fyxzlh, createdTime=Sun Jul 08 06:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1324053, encodeId=77a51324053e1, content=<a href='/topic/show?id=42b922e7350' target=_blank style='color:#2F92EE;'>#临床实践#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22773, encryptionId=42b922e7350, topicName=临床实践)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=35fc2500023, createdName=yanjie6253_56072842, createdTime=Sun Jul 08 06:23:00 CST 2018, time=2018-07-08, status=1, ipAttribution=)]

相关资讯

实战!碰到严重低钠血症,如何过关?

低钠血症是内分泌科医生临床工作中常见的一种电解质紊乱,相信大家对此都不陌生。笔者近期遇到了一例老年严重低钠血症的病例,感觉其中的诊治细节还是很值得回味。今天跟着指南带大家一起在低钠的王国闯闯关,看您能过几关。

Lupus Sci Med:仅靠LSI即可预测SLE的严重性

近期有研究者对俄克拉荷马州医学研究基金会的红斑狼疮家庭注册中心和存储库的1915名系统性红斑狼疮(SLE)的数据进行了分析。他们发现,仅仅依赖于美国风湿病学院(ACR)标准的疾病严重程度指数(LSI)的发展,是SLE活动的可靠指标。研究成果发表在近期的Lupus Sci Med。LSI是基于ACR标准风险评估模型的指标,严重的免疫抑制药物的使用(环磷酰胺、使用霉酚酸酯、环孢菌素或利妥昔单抗)也是疾

卒中治疗指南建议:支架取栓治疗严重卒中

How Stent Retriever Technology Helps Severe Strokes 

触目惊心!一例静滴药物外渗造成的严重并发症!

也许你有点不敢相信自己的眼睛,图片中,患者这只输液的手上出现的骨筋膜室综合症和张力性大疱,如此后果严重、令人触目惊心的并发症竟然是由于静脉输液药物外渗引起的!